Enlivex Therapeutics is a clinical stage immunotherapy company, developing Allocetra, a cell therapy designed to reprogram macrophages into their homeostatic state. Co. is focused on three main clinical verticals: sepsis; COVID-19; and solid tumors (the Indications). Co. is developing Allocetra as an adjunctive immunomodulating cell therapy for avoiding organ failure caused by sepsis. The drug would be administered intravenously to the patient following the diagnosis of sepsis in addition to standard of care treatment. Co. is also developing Allocetra as a solid cancer immunotherapy. The ENLV average annual return since 2014 is shown above.
The Average Annual Return on the ENLV average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ENLV average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ENLV average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|